Security key
48301N104
Kairos Pharma, LTD. - Common Stock, par value $0.001 per share (KAPA)
CUSIP: 48301N104
Q4 2025 13F Holders as of 31 Dec 2025
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 855,718
- Total 13F value
- $607,468
- Share change
- +410,699
- SEC-reported price per share
- $0.71
- Number of holders
- 14
- Value change
- +$259,407
- Number of buys
- 8
- Number of sells
- 7
- Shares outstanding
- 17,734,228
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2025
Institutions
14
Top holders
10
KAPA full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2026
Previous quarter: Q3 2025
Kairos Pharma, LTD. SEC filings
Kairos Pharma, LTD. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 48301N104
Recent filing periods:
Ownership snapshot
Top reported holders of KAPA - Kairos Pharma, LTD. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
John S. Yu
Comparable rows
15/15
Latest evidence
08 Oct 2025
13D/G
3/4/5
13F
Lead comparable stake: 5%
13D/G row: ARMISTICE CAPITAL, LLC
Showing 1-6 of 15 holder rows.
Quick read
ARMISTICE CAPITAL, LLC leads the comparable SEC ownership view at 5%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 5
ARMISTICE CAPITAL, LLC
5%
John S. Yu
31%
Neil Bhowmick
7.4%
Ramachandran Murali
1.7%
Doug Samuelson
1.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13D/G
|
5%
|
$628,306
884,938 shares
|
-$576,510 | 30 Jun 2025 |
| John S. Yu |
3/4/5
CEO and Chairman, Director, 10%+ Owner
|
31%
|
$6,101,344
5,546,677 shares
|
— | 08 Oct 2025 |
| Neil Bhowmick |
3/4/5
Chief Scientific Officer
|
7.4%
|
$931,334
1,311,739 shares
|
— | 08 Oct 2025 |
| Ramachandran Murali |
3/4/5
VP of Research and Development
|
1.7%
|
$329,481
299,529 shares
|
— | 08 Oct 2025 |
| Doug Samuelson |
3/4/5
Chief Financial Officer
|
1.7%
|
$322,342
293,039 shares
|
— | 08 Oct 2025 |
| Hyun W. Bae |
3/4/5
Director
|
0.41%
|
$52,092
73,370 shares
|
— | 16 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
14
Shares
855,718
Rows available
14
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
14
Q4 2025 holders
14
Holder diff
0
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend